The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Relationships between cytokines and cognitive function from pre- to post-chemotherapy in patients with breast cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steptoe, A., Hamer, M., & Chida, Y. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.03.011 · Cited by 1,278
O’Donovan, A., Hughes, B. M., Slavich, G. M., Lynch, L., Cronin, M.-T., O’Farrelly, C., & Malone, K. M. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.03.003 · Cited by 296
Tun, P. A., & Lachman, M. E. (2006) · Age and Ageing · doi:10.1093/ageing/afl095 · Cited by 249
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.007 · Cited by 209
Research works printed but not linked: 45
- Ahles, 2008, Cognitive function in breast cancer patients prior to adjuvant treatment, Breast Cancer Res. Treat., 110, 143, 10.1007/s10549-007-9686-5 · DOI
- Andreotti, 2015, Cancer, coping, and cognition: a model for the role of stress reactivity in cancer-related cognitive decline, Psychooncology, 24, 617, 10.1002/pon.3683 · DOI
- Bettcher, 2019, Increases in a pro-inflammatory chemokine, MCP-1, are related to decreases in memory over time, Front. Aging Neurosci., 11, 25, 10.3389/fnagi.2019.00025 · DOI
- Castel, 2017, Biomarkers associated with cognitive impairment in treated cancer patients: potential predisposition and risk factors, Front. Pharmacol., 8, 138, 10.3389/fphar.2017.00138 · DOI
- Cerulla, 2017, Role of taxanes in chemotherapy-related cognitive impairment: a prospective longitudinal study, Breast Cancer Res. Treat., 164, 179, 10.1007/s10549-017-4240-6 · DOI
- Cheung, 2015, Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study, Ann. Oncol., 26, 1446, 10.1093/annonc/mdv206 · DOI
- Drachman, 1972, Memory impairment in the aged: storage versus retrieval deficit, J. Exp. Psychol., 93, 302, 10.1037/h0032489 · DOI
- Fray, 1996, CANTAB battery: proposed utility in neurotoxicology, Neurotoxicol. Teratol., 18, 499, 10.1016/0892-0362(96)00027-X · DOI
- Ganz, 2011, Does circulating tumor necrosis factor (TNF) play a role in post-chemotherapy cerebral dysfunction in breast cancer survivors (BCS)?, J. Clin. Oncol., 29, 9008, 10.1200/jco.2011.29.15_suppl.9008 · DOI
- Ganz, 2013, Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction?, Brain Behav. Immun., 30, S99, 10.1016/j.bbi.2012.07.015 · DOI
- Gaudino, 1995, Construct validity in the trail making test: what makes part B harder?, J. Clin. Exp. Neuropsychol., 17, 529, 10.1080/01688639508405143 · DOI
- Goul, 1970, Effects of age and intelligence on trail making test performance and validity, Percept. Mot. Skills, 30, 319, 10.2466/pms.1970.30.1.319 · DOI
- Hayslip, 2015, Plasma TNF-alpha and soluble TNF receptor levels after doxorubicin with or without co-administration of Mesna-A randomized, cross-over clinical study, PLoS One, 10, 10.1371/journal.pone.0124988 · DOI
- Henneghan, 2018, Identifying cytokine predictors of cognitive functioning in breast cancer survivors up to 10 years post chemotherapy using machine learning, J. Neuroimmunol., 320, 38, 10.1016/j.jneuroim.2018.04.012 · DOI
- Janelsins, 2011, Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research, Support Care Cancer
- Janelsins, 2012, Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research, Support Care Cancer, 20, 831
- Janelsins, 2014, Prevalence, mechanisms, and management of cancer-related cognitive impairment, Int. Rev. Psychiatry, 26, 102, 10.3109/09540261.2013.864260 · DOI · Paper page
- Janelsins, 2018, Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study, J. Clin. Oncol., 10.1200/JCO.2018.78.6624 · DOI
- Jenkins, 2016, A feasibility study exploring the role of pre-operative assessment when examining the mechanism of 'chemo-brain' in breast cancer patients, Springerplus, 5, 390, 10.1186/s40064-016-2030-y · DOI
- Kesler, 2011, Prefrontal cortex and executive function impairments in primary breast cancer, Arch. Neurol., 8, 1447, 10.1001/archneurol.2011.245 · DOI
- Kesler, 2013, Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors, Brain Behav. Immun., 30, S109, 10.1016/j.bbi.2012.05.017 · DOI
- Kesler, 2016, Neurotoxic effects of Anthracycline- vs Nonanthracycline-based chemotherapy on cognition in breast cancer survivors, JAMA Oncol., 2, 185, 10.1001/jamaoncol.2015.4333 · DOI
- Korde, 2021, Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline, J. Clin. Oncol., 39, 1485, 10.1200/JCO.20.03399 · DOI
- Lee, 2018, Plasma MCP-1 and cognitive decline in patients with Alzheimer’s disease and mild cognitive impairment: a two-year follow-up study, Sci. Rep., 8, 1280, 10.1038/s41598-018-19807-y · DOI
- Lezak, 1979, Recovery of memory and learning functions following traumatic brain injury, Cortex, 15, 63, 10.1016/S0010-9452(79)80007-6 · DOI
- Lyon, 2016, Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer, J. Neuroimmunol., 301, 74, 10.1016/j.jneuroim.2016.11.002 · DOI
- Maggio, 2006, Interleukin-6 in aging and chronic disease: a magnificent pathway, J. Gerontol. A Biol. Sci. Med. Sci., 61, 575, 10.1093/gerona/61.6.575 · DOI
- Miller, 2013, Cytokine targets in the brain: impact on neurotransmitters and neurocircuits, Depress. Anxiety, 30, 297, 10.1002/da.22084 · DOI · Paper page
- Mills, 2008, Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer, Brain Behav. Immun., 22, 98, 10.1016/j.bbi.2007.07.001 · DOI
- Oppegaard, 2021, Cancer-related cognitive impairment is associated with perturbations in inflammatory pathways, Cytokine, 148, 10.1016/j.cyto.2021.155653 · DOI
- Patel, 2015, Inflammatory biomarkers, comorbidity, and neurocognition in women with newly diagnosed breast cancer, J. Natl. Cancer Inst., 107, 10.1093/jnci/djv131 · DOI
- Pusztai, 2004, Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy, Cytokine, 25, 94, 10.1016/j.cyto.2003.10.004 · DOI
- Rasmusson, 1995, Stability of performance on the Hopkins verbal learning test, Arch. Clin. Neuropsychol., 10, 21, 10.1093/arclin/10.1.21 · DOI
- Ren, 2017, Dysregulation of cytokine mediated chemotherapy induced cognitive impairment, Pharmacol. Res., 117, 267, 10.1016/j.phrs.2017.01.001 · DOI
- Robbins, 1994, Cambridge neuropsychological test automated battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers, Dementia, 5, 266
- Rodriguez Martin, 2020, Study of chemotherapy-induced cognitive impairment in women with breast Cancer, Int. J. Environ. Res. Public Health, 17, 10.3390/ijerph17238896 · DOI
- Shapiro, 1999, Construct and concurrent validity of the Hopkins verbal learning test-revised, Clin. Neuropsychol., 13, 348, 10.1076/clin.13.3.348.1749 · DOI
- Svob Strac, 2016, The serotonergic system and cognitive function, Transl. Neurosci., 7, 35, 10.1515/tnsci-2016-0007 · DOI
- Villani, 2008, Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease, Tumori, 94, 803, 10.1177/030089160809400605 · DOI
- Von Ah, 2013, Impact of perceived cognitive impairment in breast cancer survivors, Eur. J. Oncol. Nurs., 17, 236, 10.1016/j.ejon.2012.06.002 · DOI
- Wang, 2015, Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy, Cytokine, 72, 86, 10.1016/j.cyto.2014.12.006 · DOI
- Wardill, 2016, Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction, Int. J. Cancer, 139, 2635, 10.1002/ijc.30252 · DOI
- Wefel, 2004, The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial, Cancer, 100, 2292, 10.1002/cncr.20272 · DOI
- Wefel, 2015, Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults, CA Cancer J. Clin., 65, 123
- Williams, 2018, Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy, J. Neuroimmunol., 314, 17, 10.1016/j.jneuroim.2017.10.005 · DOI
Metadata
- Authors
- Janelsins, M. C., Lei, L., Netherby-Winslow, C., Kleckner, A. S., Kerns, S., Gilmore, N., Belcher, E., Thompson, B. D., Werner, Z. A., Hopkins, J. O., Long, J., Cole, S., & Culakova, E.
- Venue
- Journal of Neuroimmunology
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 362
- Pages
- 577769
- ISSN
- 0165-5728
- Cited by
- 27
- References
- 4
- Language
- en
- Licence
- Funders
- National Institutes of Health
- National Cancer Institute (K07CA168886, K07CA187546, R01CA231014, T32 CA102618, U10CA037420, UG1CA189961)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.